MaculaGen Genetic Test

Don't Gamble With Your Vision.

Results are used for planning and clinician-guided decisions.

Order a Test See How It Works

MostpeopletreatAMDwithastandardplan.

But your risk isn't standard — it's personal.

For some patients, formulation choice matters.

For roughly 1 in 6 people, the wrong supplement choice may increase risk.

Your genetics can clarify risk — and guide decisions.

Know your risk window. Plan the next steps.

View Sample Report Order Now

Scroll

What You Receive

A Report Built for Action

Clear risk windows, personalized guidance, and a comprehensive report designed for both patients and clinicians.

Close-up macro photograph of a human eye iris

2-, 5-, and 10-Year Risk Windows

See your estimated progression risk over time with clear, defined time horizons — so you and your doctor know exactly when to act.

2-Year

Risk Window

5-Year

Risk Window

10-Year

Risk Window

Genetics-Informed Supplement Guidance

A clearer pathway for formulation discussion based on your genetic profile.

Modifiable Risk Factor Context

Smoking, BMI, and other factors are presented in a practical, actionable way.

Comprehensive Report

Plain-language summary plus clinician-ready stratification in a single report.

View Sample Report Review Evidence

The Problem

Because Standard Isn't Always Safe

70% of AMD risk is genetic. For approximately 15% of patients, zinc-based AREDS supplements triple the risk of wet AMD. The MaculaGen® test identifies who is at risk — so treatment decisions are guided by evidence, not guesswork.

DNA double helix structure in blue lighting

0%Risk is Genetic

0%At-Risk Patients

0xIncreased Risk

0Genetic Markers

Generic Plan

One-Size-Fits-All

Same AREDS2 for all patients
No CFH/ARMS2 genetic screening
For certain genetic profiles, zinc may increase risk

Personalized Plan

Genetics-Informed

Supplement choice guided by CFH & ARMS2 genotype
Personalized risk stratification with defined time windows
2-, 5-, and 10-year progression risk windows
Backed by Harvard, Stanford, Tufts research

Better confidence, better follow-through, better outcomes

Supplements + Genetics

Stop Guessing on AREDS Formulation

A clearer conversation about what fits your biology.

15%

of patients are at risk from standard supplements

For approximately 15% of patients, zinc-based AREDS supplements (≥25 mg/day) triple the risk of progression to wet AMD.

For Patients

Zinc-based eye vitamins like AREDS/AREDS2 are not safe for all patients. The MaculaGen test reveals whether you are harmed or helped by an AREDS formulation, and recommends a personalized supplement based on your genetics.

Research shows that approximately 15% of patients consuming AREDS2 with zinc (≥25 mg/day) face increased risk of progression to wet AMD — 3x the risk for certain genetic profiles.

Timing

The Window for Protecting Vision Is Narrower Than You Think

AMD progresses silently. By the time symptoms appear, the opportunity for meaningful intervention has already narrowed. Genetic testing identifies who needs closer monitoring — before it's too late.

Detailed macro photograph of a human eye

AMD Progression Timeline

Action WindowToo Late

Intervention Window

When Action Still Matters

Early AMDYears before symptoms

Drusen detected — no vision loss yet. Genetic testing identifies risk level.

IntermediateMonths to years

Drusen grow larger. Risk of conversion rises. Supplement and monitoring plan activated.

After Conversion

When Options Narrow

ConversionWeeks to months

Wet AMD or geographic atrophy begins. Anti-VEGF can slow — but cannot reverse.

AdvancedPermanent

Central vision lost. Reading, driving, facial recognition severely affected.

MaculaGen identifies high-risk patients in the intervention window — when a plan still makes a difference

How It Works View the Evidence

Process

Cheek Swab to Clear Next Steps

Step 01

Collect

Buccal swab — under 60 seconds

Simple cheek swab — no blood test, no venipuncture, no special handling. Collect chairside or at home with the MaculaGen test kit.

Step 02

Analyze

14 genetic markers across 12 genes

CLIA-certified laboratory analyzes 14 genetic markers including CFH and ARMS2 to determine your AMD risk profile.

Step 03

Report

Personalized risk profile

Dual report within 6–8 weeks: patient-friendly summary + clinician-ready risk stratification with 2-, 5-, 10-year windows.

Step 04

Act

Supplement + monitoring plan

Work with your clinician to choose the right supplement formulation and monitoring schedule based on your genetic profile.

Order a Test View Sample Report

Trust

Built on Evidence, Designed for Clarity

US Patent-Protected

US Patent awarded for the discovery linking CFH/ARMS2 genotype to supplement response. Foundational research backed by peer-reviewed evidence.

Proven Accuracy

Personalized risk stratification with defined time windows. Analyzes 14 genetic markers across 12 genes for 2-, 5-, and 10-year progression estimates.

Peer-Reviewed Evidence

Supported by research from Harvard, Stanford, University of Toronto, and Tufts. Key studies by Seddon (2016, BJO) and Vavvas (2018, PNAS).

Limitations

View details

Research Institutions

Dr. Pamela Weber, MD

Vitreoretinal Consultants of NY

“I routinely use genetic testing to decide on AMD supplements and to determine a patient’s risk of disease progression.”

Dr. Gregory B. Clay, O.D.

Clay-Rhynes Eye Clinic, Oklahoma

“After nearly a decade of use, I can say that MaculaGen has been a key component in preserving the vision of a multitude of our patients.”

Dr. Dorri Goldsmidt

Gardendale, Alabama

“Genetic testing is allowing me to deliver to my patients precision treatment, uniquely tailored to their specific disease status and genetic composition. This is the future of medicine for eye care professionals committed to advancing personalized care.”

Dr. Pamela Weber, MD

Vitreoretinal Consultants of NY

“I routinely use genetic testing to decide on AMD supplements and to determine a patient’s risk of disease progression.”

Dr. Gregory B. Clay, O.D.

Clay-Rhynes Eye Clinic, Oklahoma

“After nearly a decade of use, I can say that MaculaGen has been a key component in preserving the vision of a multitude of our patients.”

Dr. Dorri Goldsmidt

Gardendale, Alabama

FAQ

Common Questions

View All FAQs

What does the MaculaGen test analyze?

How is the sample collected?

Who should consider this test?

How long until I receive results?

Is this test covered by insurance?

Can this test diagnose macular degeneration?

View All FAQs

Get Started

Know Your Risk. Personalize Your Plan.

Take the next step toward personalized care — for yourself or for your patients.

Order a Test